Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
$0.00
Activity Description One out of six US adults suffer from migraines and yet, until recently, management has been reliant on treatments designed for other conditions that had some consequential success. Fortunately, this long-standing paradigm has not only ended but has accelerated in the opposite direction. The rapid acquisition of new therapies has created a near impossible amount of information to parse out efficiently.
$0.00
OverviewMultiple sclerosis (MS) is the leading cause of non-traumatic disability in adults over the age of 50 and has become a prominent focus of evolving research. In just the past two decades, a greater understanding of the pathogenesis of MS has led to a litany of new FDA approved therapies. In fact, there are now 18 disease modifying therapies (DMTs) representing nine therapeutic classes approved for use in the US with multiple late-stage medications poised to join them.
$0.00
Activity DescriptionNeuromyelitis optica spectrum disorder (NMOSD) is typically characterized by inflammation of the optic nerve and spinal cord but, more recently, has also been recognized to have cerebral or brainstem involvement. Given its clinical manifestation, NMOSD is frequently confused with other disorders such as multiple sclerosis or MOG-associated diseases and requires thorough understanding of diagnostic strategies to identify. In just the past 2 years, three agents specific to NMOSD have entered the armamentarium.
$0.00
Program DescriptionThe emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day. This issue is even more pressing for patients with conditions such as multiple sclerosis (MS) who have altered immune systems from both chronic illness and disease modifying therapies (DMTs). While the advent of vaccines has revived hope for a return to normal life, vaccination is not always straightforward for those on or planning to start immunosuppressive therapies such as MS DMT. In this activity, Drs.
$0.00
OverviewThis activity, originally held as a satellite symposium in conjunction with the 2021 Consortium of Multiple Sclerosis (MS) Centers (CMSC) Annual Meeting, is designed to contextualize contemporary management approaches through the documented experiences of people with MS. Drs Benjamin Greenberg, Jennifer Graves, and Anthony Traboulsee present data from a large cohort of patients illustrating their perspectives on a variety of management issues related to their care.
$0.00
Program DescriptionEstimated to occur in up to a third of the general population with 25 or so different causes, excessive daytime sleepiness (EDS) can be difficult to trace back to its root cause. Some of the more prevalent disorders associated with this symptom include narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH). However, the lines between these disorders have been mobile and debated for years which has made their recognition and management challenging for treating clinicians.
$0.00
Program DescriptionLevodopa, the gold standard treatment for Parkinson’s disease (PD), is associated with a variety of complications and side effects including motor fluctuations and “OFF” periods. The armamentarium for OFF management is continually expanding, with 8 new therapies approved in just the past 6 years ranging from novel carbidopa-levodopa (C/L) formulations to a variety of adjunctive mechanisms. Availability of multiple therapies coupled with a lack of head-to-head comparisons presents a challenge to clinicians as to how to choose from among these options.
$0.00
Program DescriptionMultiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years. To assist practitioners in parsing out the rationale for and clinical utitity of these and other late-stage agents, Efficient surveyed five renowned MS specialists regarding their perspectives on these advances.
$0.00
Program DescriptionThis activity is designed to highlight the differences in self-reported diagnostic and therapeutic strategies of MS specialists and general neurologists. With the help of Drs Andrew Solomon, Robert Bermel, and Jiwon Oh, Efficient, ACTRIMS, and Postgraduate Institute for Medicine conducted a case-based survey of 26 MS Experts and 100 community-based neurologists to evaluate a variety of different MS scenarios such as their competency with the McDonald criteria and use of new agents.
$0.00
Program DescriptionEpilepsy syndromes are historically difficult to diagnose and treat effectively due to their widely varying etiologies and presentations and their high probability of drug-resistance. With the influx of newly discovered and potentially targetable genetic etiologies driving epilepsy, long-held standards in diagnosis and management of these populations are being upended.